Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

olodaterol

- PMLiVE

AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug

Results from a phase 3 trial showed Enhertu reduced the risk of disease progression or death by 50%

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval

Breast cancer is the most diagnosed type of cancer worldwide, with an estimated 2.3 million patients diagnosed in 2020

- PMLiVE

Boehringer Ingelheim and QUANTRO Therapeutics partner to develop drug candidates

The collaboration aims to offer a long-term strategy to provide breakthrough cancer treatments

- PMLiVE

AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab

The INTERLINK-1 study assessed the combination drug candidate to treat patients with head and neck cancer

- PMLiVE

AstraZeneca’s Tezspire recommended for approval in the EU by CHMP

The recommendation is for the treatment of severe asthma as an add-on therapy for patients 12 years and above

- PMLiVE

Expert review shows AstraZeneca’s COVID-19 vaccine is ‘equally effective’ as mRNA vaccines

The study informs policymakers about the optimal deployment of COVID-19 vaccines over the next 12 months

- PMLiVE

Boehringer Ingelheim and VisionHealth collaborate on distribution of digital Kata platform

The app provides therapy support to those with with asthma and chronic obstructive pulmonary disease

- PMLiVE

Evotech, Boehringer Ingelheim and bioMérieux launch joint venture to combat antimicrobial resistance

The joint company, Aurobac Therapeutics SAS, will create the next generation of antimicrobials along with actionable diagnostics to combat antimicrobial resistance

- PMLiVE

First evidence-based guide launched to put patients at heart of digital innovations

Produced by the University of Plymouth, the Academic Health Science Network and Boehringer Ingelheim, the guide follows the UK government’s plan to revolutionise digital health and social care

- PMLiVE

AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn

The acquisition includes TeneoTwo’s phase 1 clinical-stage T-cell engager

- PMLiVE

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

The results show that the Lynparza combination therapy significantly improved radiographic progression-free survival

- PMLiVE

FDA approves GSK’s Priorix vaccine for measles, mumps and rubella

The vaccine has been approved to use in those aged 12 months and above

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links